Syndax ($SNDX) podcast mentions
Timestamped Syndax ($SNDX) mentions across our podcast corpus.
Sure. Those were, uh, 3 separate companies that were each bought now for, uh, $10 billion or more. And things they have in common, uh, Krenetics was, uh, commercial stage and Nuvalent and Apigee, let's say late stage clinical. I think that bodes well just for the kind of names we own in the portfolio. But I want to stress to those listening, if you've heard me before, you know I say this a lot, that buyouts are the icing on the cake for me. I've been fortunate that I've been taught and learned from a lot of people way smarter than me. And one of them, Biotech Phoenix, from our chat, who was on the board of several companies early on, he instilled in me that one of my selection criteria for stocks needs to be high strategic value to acquirers. So it can be a valuable platform platform technology, a drug in an area where there's less competition or where it's clearly better than the competition, et cetera. An example might be Syndax Pharmaceuticals, SNDX, that we bought for around $9 a share. And it already had, I think it was just under $9 actually, and it already had 2 approved drugs. So it was not a science project. We were looking at the sales growth for RevuForge in AML and Nectimbo in graft versus host disease. 2026, '27, '28, where do we think those go? Also via label expansions. I think that's around 22 or something right now. And, you know, people keep asking for the updated game plan expecting something exciting from me, but I'm just holding these names patiently. Like I said, they report the results, these companies, once every 3 months. If thesis is going in the right direction, hold patiently. That's where the big money is made. And, you know, if something comes out that shows me I'm wrong, I'll be the first person to open my mouth, insert foot, sell it, and move on. But what's nice here with, uh, Syndax as an example, uh, they have a 50/50 US split for the Nectimvo drug, uh, with, uh, Incyte. So of course there's speculation that at some point Incyte might want to buy out Syndax for to bolster their hematology franchise. If that happens, great.
Jonathan Fazon · Investing Experts · Biotech euphoria driven by fundamentals · 2026-07-08